Get access

Post-market drug safety evidence sources: an analysis of FDA drug safety communications

Authors

  • Chieko Ishiguro,

    Research Expert
    1. Division of Surveillance and Analysis, Office of Safety I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan
    Search for more papers by this author
  • Marni Hall,

    1. Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA
    Search for more papers by this author
  • George A. Neyarapally,

    Corresponding author
    • Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA
    Search for more papers by this author
  • Gerald Dal Pan

    1. Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA
    Search for more papers by this author

  • Ms. Ishiguro conducted this research when she was a visiting scientist in the Office of Surveillance and Epidemiology, CDER, FDA in 2010.

G. A. Neyarapally, PharmD, MPH, Interdisciplinary Scientist, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Building 22, Room 4461, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA. E-mail: George.neyarapally@fda.hhs.gov

No abstract is available for this article.

Ancillary